Treister AD, et al. - Researchers described the characteristics of patients who develop conjunctivitis secondary to dupilumab treatment for atopic dermatitis (AD) in this case series of 12 patients. Results of this study suggested that conjunctivitis that develops after administration of dupilumab to treat AD might be severe enough to necessitate stopping therapy. In patients with more severe baseline AD who had a good response to dupilumab and an increased atopic phenotype, severe conjunctivitis was more likely to develop.